Status: Recruiting
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.
Participants needed: 290
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Crescent Biopharma, Inc.Updated: Sep 10, 2026Locations: 31
Eligibility criteria
Life expectancy ≥ 3 months [+12]
Has malignancies other than disease under study within the past 3 years [+12]